Why the study?
This review analyzes currently available commercial, investigational, and preclinical transcatheter aortic valve replacement valves, highlighting clinical circumstances where specific devices may be favoured over others.
This review provides a comprehensive overview of current and investigational TAVR valves, comparing their design features and clinical outcomes to guide valve selection.
Answers are grounded in this paper and cite their sources.
May guide individualized TAVR valve selection by design features; leaves open need for head-to-head RCTs to confirm preferences.
PURPOSE OF REVIEW: This review analyzes currently available commercial transcatheter aortic valve replacement (TAVR) valves as well as valves in investigational status and those in preclinical testing. The design features and clinical outcomes of the Edwards SAPIEN S3 and Medtronic Evolut PRO+ are described and compared with highlight clinical circumstances where one may be favoured over the other. RECENT FINDINGS: Multiple randomized and nonrandomized trials have compared commercial and investigational TAVR valves. The results of these are summarized and discussed within this review with a focus on how the SAPIEN S3 and Evolut PRO+ both compare to each other as well as various valves in different investigational stages. SUMMARY: TAVR is an innovative and ground-breaking technology that will forever have revolutionized the management of aortic stenosis. Though the technology and valves themselves have come a long way, further developments are necessary if we are to continue to expand its indications and achieve a safer perioperative experience with more durable valves.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: